VPS35L: A Potential Drug Target and Biomarker for Esophageal Cancer

Target Name: VPS35L

NCBI ID: G57020

VPS35L

VPS35L: A Potential Drug Target and Biomarker for Esophageal Cancer

Esophageal cancer is a leading cause of cancer-related deaths worldwide, with poor prognosis and limited treatment options. Despite advances in surgical and radiation therapy, the survival rate for advanced esophageal cancer remains high. Therefore, there is a need for new treatments and biomarkers to improve patient outcomes.

VPS35L, a protein that is expressed in various tissues and cells, including esophagus, has been identified as a potential drug target and biomarker for esophageal cancer.

The Identification of VPS35L as a Potential Drug Target

VPS35L is a member of the VPS family, which includes proteins that are involved in various cellular processes, including cell division, migration, and invasion. VPS35L is expressed in various tissues, including the esophagus, and has been shown to be involved in cell signaling pathways that are critical for esophageal cancer development.

Studies have shown that VPS35L is involved in the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). Therefore, VPS35L may be a useful target for drugs that can inhibit these processes.

The Potential Role of VPS35L as a Biomarker for Esophageal Cancer

Esophageal cancer is often diagnosed through endoscopy, which involves inserting a thin, flexible tube through the nose and into the esophagus to examine any suspicious areas. This procedure can cause damage to the esophagus, making it difficult to obtain reliable results from endoscopy. Therefore, there is a need for biomarkers that can be used as alternatives to endoscopy.

VPS35L has been shown to be expressed in various types of esophageal cancer, including adenocarcinoma (a common type of esophageal cancer) and squamous cell carcinoma (SCC). Therefore, VPS35L may be a useful biomarker for esophageal cancer, particularly in cases where endoscopy is not possible or reliable.

The Identification of VPS35L as a Potential Drug Target and Biomarker for Esophageal Cancer

In conclusion, VPS35L is a protein that has been identified as a potential drug target and biomarker for esophageal cancer. The regulation of cell growth, apoptosis, and angiogenesis by VPS35L may make it an attractive target for small molecules that can inhibit these processes. Further studies are needed to confirm the potential of VPS35L as a drug target and biomarker for esophageal cancer.

Protein Name: VPS35 Endosomal Protein Sorting Factor Like

Functions: Acts as component of the retriever complex. The retriever complex is a heterotrimeric complex related to retromer cargo-selective complex (CSC) and essential for retromer-independent retrieval and recycling of numerous cargos such as integrin alpha-5/beta-1 (ITGA5:ITGB1) (PubMed:28892079). The recruitment of the retriever complex to the endosomal membrane involves CCC and WASH complexes (PubMed:28892079). In the endosomes, drives the retrieval and recycling of NxxY-motif-containing cargo proteins by coupling to SNX17, a cargo essential for the homeostatic maintenance of numerous cell surface proteins associated with processes that include cell migration, cell adhesion, nutrient supply and cell signaling (PubMed:28892079). Involved in copper-dependent ATP7A trafficking between the trans-Golgi network and vesicles in the cell periphery; the function is proposed to depend on its association with the CCC complex and cooperation with the WASH complex on early endosomes. Seems not to be required for CCC complex stability (PubMed:25355947)

The "VPS35L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VPS35L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets